famitinib po + HS-10296 po
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR-mutant Non-Small Cell Lung Cancer
Conditions
EGFR-mutant Non-Small Cell Lung Cancer
Trial Timeline
Apr 25, 2019 → Dec 1, 2022
NCT ID
NCT03904823About famitinib po + HS-10296 po
famitinib po + HS-10296 po is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for EGFR-mutant Non-Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03904823. Target conditions include EGFR-mutant Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03904823 | Phase 2 | UNKNOWN |
Competing Products
2 competing products in EGFR-mutant Non-Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinib | Novartis | Phase 1 | 33 |